Literature DB >> 29477761

Concurrent Assessment of the Antinociceptive and Behaviorally Disruptive Effects of Opioids in Squirrel Monkeys.

Sarah L Withey1, Carol A Paronis2, Jack Bergman2.   

Abstract

Although the clinical application of opioids for pain management is often hindered by undesired behavioral impairment, preclinical assays of antinociception typically do not provide information regarding the behaviorally disruptive effects of opioids that may accompany their antinociceptive effects. To address this, we modified a warm water tail withdrawal procedure to determine concurrently the effects of opioids on tail withdrawal latency (antinociception) and indices of food-maintained operant behavior (rates of responding and reinforcement density) in squirrel monkeys. Six opioid agonists were tested, and all produced dose-dependent antinociception and impairment of operant behavior. The ratio of median effective dose (ED50) values for both measures (behavioral impairment:antinociception) was used as a quantitative measure of therapeutic index. Nalbuphine had the highest ED50 ratio (4.88), reflecting antinociception with minimal behavioral disruption. Oxycodone, heroin, buprenorphine, and methadone all produced similar ED50 ratios (.82-1.14), whereas butorphanol yielded a significantly lower ED50 ratio (.17) reflecting behavioral disruption at doses producing only minimal antinociception. The antinociceptive and behaviorally disruptive effects of oxycodone and buprenorphine were further characterized using Schild analysis to calculate apparent pA2 values for antagonism of the 2 drugs by naltrexone. These analyses suggest that µ-receptor mechanisms likely mediate the antinociceptive as well as behaviorally disruptive effects of oxycodone (pA2 values: 8.13 and 8.57) and buprenorphine (pA2 values: 8.6 and 7.9). PERSPECTIVE: This article presents an assay that allows for the concurrent assessment of the antinociceptive and behaviorally disruptive effects of opioids. Our results show that the tail withdrawal assay in squirrel monkeys can provide a useful index of the behavioral selectivity with which opioids produce antinociception.
Copyright © 2018 The American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Opioid; antinociception; oxycodone; schedule-controlled behavior; squirrel monkey

Mesh:

Substances:

Year:  2018        PMID: 29477761      PMCID: PMC6026058          DOI: 10.1016/j.jpain.2018.02.003

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  57 in total

1.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

2.  Determination of receptors that mediate opiate side effects in the mouse.

Authors:  A G Hayes; M B Tyers
Journal:  Br J Pharmacol       Date:  1983-07       Impact factor: 8.739

3.  Agonist and antagonist actions of morphine-like drugs on the guinea-pig isolated ileum.

Authors:  E A Gyand; H W Kosterlitz
Journal:  Br J Pharmacol Chemother       Date:  1966-09

Review 4.  Nalbuphine.

Authors:  W K Schmidt; S W Tam; G S Shotzberger; D H Smith; R Clark; V G Vernier
Journal:  Drug Alcohol Depend       Date:  1985-02       Impact factor: 4.492

5.  In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats.

Authors:  E A Walker; M M Makhay; J D House; A M Young
Journal:  J Pharmacol Exp Ther       Date:  1994-11       Impact factor: 4.030

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  Acute and chronic morphine administration: effects of mixed-action opioids in rats and squirrel monkeys responding under a schedule of food presentation.

Authors:  A H Oliveto; M J Picker; L A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  1991-04       Impact factor: 4.030

8.  Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys.

Authors:  Patrick M Beardsley; Mario D Aceto; Charles D Cook; Edward R Bowman; Jennifer L Newman; Louis S Harris
Journal:  Exp Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.157

9.  In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.

Authors:  A Kuo; B D Wyse; W Meutermans; M T Smith
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

10.  Morphine-like stimulus effects in the monkey: opioids with antagonist properties.

Authors:  G J Schaefer; S G Holtzman
Journal:  Pharmacol Biochem Behav       Date:  1981-02       Impact factor: 3.533

View more
  9 in total

1.  Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.

Authors:  Kathryn L Schwienteck; S Stevens Negus; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2019-06       Impact factor: 2.293

2.  Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.

Authors:  Shawn M Flynn; Phillip M Epperly; April T Davenport; Gerta Cami-Kobeci; Stephen M Husbands; Mei-Chuan Ko; Paul W Czoty
Journal:  Neuropsychopharmacology       Date:  2019-04-10       Impact factor: 7.853

3.  Developing Improved Translational Models of Pain: A Role for the Behavioral Scientist.

Authors:  Sarah L Withey; David R Maguire; Brian D Kangas
Journal:  Perspect Behav Sci       Date:  2020-01-03

4.  Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.

Authors:  Sarah L Withey; Roger D Spealman; Jack Bergman; Carol A Paronis
Journal:  J Pharmacol Exp Ther       Date:  2019-08-14       Impact factor: 4.030

5.  Discrimination learning in oxycodone-treated nonhuman primates.

Authors:  Sarah L Withey; Rachel J Doyle; Erica N Porter; Jack Bergman; Brian D Kangas
Journal:  Drug Alcohol Depend       Date:  2019-11-27       Impact factor: 4.492

6.  Enhancement of Opioid Antinociception by Nicotine.

Authors:  Fernando Barreto de Moura; Sarah Louise Withey; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2019-09-16       Impact factor: 4.030

7.  Enhancement of Opioid Antinociception by Nicotinic Ligands.

Authors:  Fernando B de Moura; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2021-01-13       Impact factor: 4.030

8.  A Journey through Diastereomeric Space: The Design, Synthesis, In Vitro and In Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and Antagonists.

Authors:  Dana R Chambers; Agnieszka Sulima; Dan Luo; Thomas E Prisinzano; Alexander Goldberg; Bing Xie; Lei Shi; Carol A Paronis; Jack Bergman; Nima Nassehi; Dana E Selley; Gregory H Imler; Arthur E Jacobson; Kenner C Rice
Journal:  Molecules       Date:  2022-09-30       Impact factor: 4.927

9.  The Intriguing Effects of Substituents in the N-Phenethyl Moiety of Norhydromorphone: A Bifunctional Opioid from a Set of "Tail Wags Dog" Experiments.

Authors:  Meining Wang; Thomas C Irvin; Christine A Herdman; Ramsey D Hanna; Sergio A Hassan; Yong-Sok Lee; Sophia Kaska; Rachel Saylor Crowley; Thomas E Prisinzano; Sarah L Withey; Carol A Paronis; Jack Bergman; Saadet Inan; Ellen B Geller; Martin W Adler; Theresa A Kopajtic; Jonathan L Katz; Aaron M Chadderdon; John R Traynor; Arthur E Jacobson; Kenner C Rice
Journal:  Molecules       Date:  2020-06-06       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.